康恩贝：吸入用复方异丙托溴铵溶液获药品注册证书

Group 1 - The core point of the article is that Kang En Bei has received approval from the National Medical Products Administration for its inhalation solution containing compound ipratropium bromide, which is intended for patients requiring multiple bronchodilators for the treatment of reversible bronchospasm related to obstructive airway diseases [1] - The product is expected to address a market demand, with projected sales in the domestic retail and medical terminal market amounting to 240 million yuan in 2024 [1]